278 related articles for article (PubMed ID: 18569389)
1. The opioid antagonist naltrexone improves murine inflammatory bowel disease.
Matters GL; Harms JF; McGovern C; Fitzpatrick L; Parikh A; Nilo N; Smith JP
J Immunotoxicol; 2008 Apr; 5(2):179-87. PubMed ID: 18569389
[TBL] [Abstract][Full Text] [Related]
2. Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: attenuation of pro-inflammatory gene expression.
Kwon KH; Murakami A; Tanaka T; Ohigashi H
Biochem Pharmacol; 2005 Feb; 69(3):395-406. PubMed ID: 15652231
[TBL] [Abstract][Full Text] [Related]
3. The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease.
Lu F; Fernandes SM; Davis AE
Am J Physiol Gastrointest Liver Physiol; 2010 Jun; 298(6):G878-83. PubMed ID: 20338925
[TBL] [Abstract][Full Text] [Related]
4. Dextran sulphate sodium induces acute colitis and alters hepatic function in hamsters.
Karlsson A; Jägervall A; Pettersson M; Andersson AK; Gillberg PG; Melgar S
Int Immunopharmacol; 2008 Jan; 8(1):20-7. PubMed ID: 18068096
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1beta targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis.
Kwon KH; Murakami A; Hayashi R; Ohigashi H
Biochem Biophys Res Commun; 2005 Nov; 337(2):647-54. PubMed ID: 16202978
[TBL] [Abstract][Full Text] [Related]
6. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model.
Ghia JE; Blennerhassett P; Kumar-Ondiveeran H; Verdu EF; Collins SM
Gastroenterology; 2006 Oct; 131(4):1122-30. PubMed ID: 17030182
[TBL] [Abstract][Full Text] [Related]
7. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis.
Mikami S; Nakase H; Yamamoto S; Takeda Y; Yoshino T; Kasahara K; Ueno S; Uza N; Oishi S; Fujii N; Nagasawa T; Chiba T
J Pharmacol Exp Ther; 2008 Nov; 327(2):383-92. PubMed ID: 18716065
[TBL] [Abstract][Full Text] [Related]
8. Nonmyeloablative stem cell therapy enhances microcirculation and tissue regeneration in murine inflammatory bowel disease.
Khalil PN; Weiler V; Nelson PJ; Khalil MN; Moosmann S; Mutschler WE; Siebeck M; Huss R
Gastroenterology; 2007 Mar; 132(3):944-54. PubMed ID: 17383423
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells.
Aharoni R; Sonego H; Brenner O; Eilam R; Arnon R
Immunol Lett; 2007 Oct; 112(2):110-9. PubMed ID: 17719654
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
Nakase H; Okazaki K; Tabata Y; Chiba T
J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease.
Shteingart S; Rapoport M; Grodzovski I; Sabag O; Lichtenstein M; Eavri R; Lorberboum-Galski H
Gut; 2009 Jun; 58(6):790-8. PubMed ID: 18978179
[TBL] [Abstract][Full Text] [Related]
12. Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease.
Melgar S; Karlsson L; Rehnström E; Karlsson A; Utkovic H; Jansson L; Michaëlsson E
Int Immunopharmacol; 2008 Jun; 8(6):836-44. PubMed ID: 18442787
[TBL] [Abstract][Full Text] [Related]
13. Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/ CD13)--a novel approach for the treatment of inflammatory bowel disease.
Bank U; Heimburg A; Helmuth M; Stefin S; Lendeckel U; Reinhold D; Faust J; Fuchs P; Sens B; Neubert K; Täger M; Ansorge S
Int Immunopharmacol; 2006 Dec; 6(13-14):1925-34. PubMed ID: 17161345
[TBL] [Abstract][Full Text] [Related]
14. Chrysin, a natural flavone, improves murine inflammatory bowel diseases.
Shin EK; Kwon HS; Kim YH; Shin HK; Kim JK
Biochem Biophys Res Commun; 2009 Apr; 381(4):502-7. PubMed ID: 19233127
[TBL] [Abstract][Full Text] [Related]
15. Dietary lactoferrin does not prevent dextran sulfate sodium induced murine intestinal lymphocyte death.
Spagnuolo PA; Hoffman-Goetz L
Exp Biol Med (Maywood); 2008 Sep; 233(9):1099-108. PubMed ID: 18535168
[TBL] [Abstract][Full Text] [Related]
16. Antioxidants as novel therapy in a murine model of colitis.
Oz HS; Chen TS; McClain CJ; de Villiers WJ
J Nutr Biochem; 2005 May; 16(5):297-304. PubMed ID: 15866230
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of inflammatory bowel disease in a mouse model of depression.
Ghia JE; Blennerhassett P; Deng Y; Verdu EF; Khan WI; Collins SM
Gastroenterology; 2009 Jun; 136(7):2280-2288.e1-4. PubMed ID: 19272381
[TBL] [Abstract][Full Text] [Related]
18. Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice.
Sakata A; Ochiai T; Shimeno H; Hikishima S; Yokomatsu T; Shibuya S; Toda A; Eyanagi R; Soeda S
Immunology; 2007 Sep; 122(1):54-64. PubMed ID: 17451462
[TBL] [Abstract][Full Text] [Related]
19. Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice.
Ito R; Kita M; Shin-Ya M; Kishida T; Urano A; Takada R; Sakagami J; Imanishi J; Iwakura Y; Okanoue T; Yoshikawa T; Kataoka K; Mazda O
Biochem Biophys Res Commun; 2008 Dec; 377(1):12-6. PubMed ID: 18796297
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
Aharoni R; Kayhan B; Brenner O; Domev H; Labunskay G; Arnon R
J Pharmacol Exp Ther; 2006 Jul; 318(1):68-78. PubMed ID: 16624971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
